www.urologiepropraxi.cz / Urol. praxi. 2024;25(1):16-21 / UROLOGIE PRO PRAXI 21 PŘEHLEDOVÉ ČLÁNKY Kombinovaná farmakoterapie symptomů dolních cest močových 8. Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554-1566. 9. Barkin J, Guimarães M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461-466. 10. Nickel JC, Barkin J, Koch C, et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J. 2008;2(1):16-21. 11. Matoušková M, Hanuš T. Kombinovaná léčba u symptomů dolních močových cest a benigní hyperplazie prostaty. Urol. praxi. 2011;12(1):7-11. 12. Gacci M, Sebastianelli A, Salvi M, et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015;16(9):60. 13. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003-1012. 14. Drake MJ, Oelke M, Snijder R, et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One. 2017;12(2):e0170726. 15. Kim HJ, Sun HY, Choi H, et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS One. 2017;12(1):e0169248. 16. Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron Add- -on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus. 2020;6(4):729-737. 17. Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol. 2020;203(6):1163-1171. 18. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2017;35(5):827-838. 19. Soliman MG, El-Abd SA, Tawfik AM, et al. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol. 2021;39(6):2049-2054. 20. Nagasubramanian S, John NT, Antonisamy B, et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int. 2020;125(5):718-724. 21. Porst H, Oelke M, Goldfischer ER, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82(3):667-673. 22. Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011;107(7):1110-1116. 23. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. 24. Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727-733. 25. van Kerrebroeck P, Rezapour M, Cortesse A, et al. Desmopressin in the treatment of nocturia: a double-blind, placebo- -controlled study. Eur Urol. 2007;52(1):221-229. 26. Drlík P. Nykturie – současné možnosti terapie. Urol. praxi. 2010;11(4):176-179. 26. ročník Moravského urologického sympozia 20.–21. 5. 2024 Hotel Sepetná MÍSTO KONÁNÍ Hotel Sepetná Ostravice, www.sepetna.cz Aktuální informace sledujte na www.kongresurologie.cz
RkJQdWJsaXNoZXIy NDA4Mjc=